Stavroula Manolakou, Medical Oncologist, cooperator IASIS General Clinic (Chania), outpatient office in Chania and Rethymno, Crete, shared a post on LinkedIn:
“Excited to attend the ESMO Gynaecological Cancers Congress 2026 in Copenhagen, where leading experts gathered to share the latest advances in gynecologic oncology. As a Medical Oncologist with a special interest in gynecological cancers, I feel grateful for the opportunity to learn, collaborate, and stay at the forefront of innovation in ovarian, endometrial, cervical, vulvar, and rare gynecologic cancers.
Key highlights from ESMO Gynae 2026 that caught my attention:
Immunotherapy continues to reshape the treatment landscape of gynecologic cancers, particularly in dMMR endometrial cancer, with growing evidence supporting earlier and more effective use of immune checkpoint inhibitors.
Bispecific antibodies emerged as an exciting therapeutic platform, demonstrating promising activity and opening new opportunities for immune-based treatment approaches.
Antibody-drug conjugates (ADCs) remain at the forefront of innovation, with encouraging results across ovarian, endometrial, and cervical cancers.
New therapeutic strategies for platinum-resistant ovarian cancer were among the most exciting developments of the congress, including novel ADCs, bispecific antibodies, and other targeted approaches that may address a major unmet clinical need.
HER2-directed therapies continue to expand treatment options, reinforcing the importance of comprehensive molecular profiling.
Emerging targets such as B7-H4 and Nectin-4 showed promising clinical activity, highlighting the growing arsenal of precision therapies in gynecologic oncology.
An inspiring meeting in Copenhagen that showcased the remarkable pace of innovation in gynecologic oncology and strengthened our commitment to translating cutting-edge science into improved patient outcomes.”
Other articles about ESMO on OncoDaily.
